Press release 📈 Stocks 🌍 United States ISIN US00287Y1091

AbbVie Reports Positive Phase 1 Data for Metabolic Drug Candidate ABBV-295

AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.

📅 September 30, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: ABBV ↑ 6/10 (60% confidence).

📊 Affected Assets (1)

ABBV

Bullish 🤖 60%

📆 Mid-term 🌍 US · Explicit

AbbVie presented favorable Phase 1 data for ABBV-295, showing a long half-life and dose-proportional exposure, supporting less frequent dosing and advancing its metabolic pipeline.

🎯 Key Takeaways

ABBV-295 demonstrated a 11- to 12-day half-life in Phase 1 clinical trials.
Dose-proportional exposure supports the feasibility of bi-weekly or less frequent dosing intervals.
The findings bolster AbbVie's strategic expansion into the metabolic disease market.

📝 Executive Summary

AbbVie announced favorable Phase 1 clinical results for its metabolic pipeline candidate, ABBV-295. The data indicates a 11- to 12-day half-life and dose-proportional plasma exposure, providing a strong foundation for less frequent dosing schedules.

❓ FAQ

What is the significance of the ABBV-295 Phase 1 results?

The results confirm favorable pharmacokinetic properties, specifically a long half-life, which allows for more convenient dosing schedules for patients.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article